AFT makes further progress in international markets

AFT Pharmaceuticals Limited,
Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com








4 March 2024
AFT makes further progress in international markets.
AFT Pharmaceuticals (NZX: AFT, ASX: AFP) today provides an update on recent
progress it has made in international markets.
Maxigesic
®
Rapid key manufacturing agreement
1

AFT has partnered with the US-based pharmaceutical manufacturer Microsize
on a long-term supply agreement of micronized active pharmaceutical
ingredients (APIs), critical components of AFT’s Maxigesic Rapid pain relief
medicine.
The Microsize agreement will assist AFT to source sufficient materials to supply
Maxigesic Rapid in a number of markets including the US and EU.
Maxigesic Rapid, which is under the Combogesic brand in many markets, is a
fast-dissolving tablet formulation of AFT’s Maxigesic family of pain relief
medicines. Maxigesic Rapid allows faster release of the active ingredients,
especially the ibuprofen component of the medicine. The rapid formulation
has a patent until 2039, issued and under examination, in a number of
countries, including the US where the patent has been granted.
AFT Managing Director Dr Hartley Atkinson commented: “We are very pleased
to work with Microsize which has considerable expertise in the micronization
technology that is crucial for the new rapid release Maxigesic/Combogesic
formulation.”

Microsize CEO TJ Higley commented: “We are excited to have been chosen
as the commercial partner to supply the blended/micronized drug product
intermediate for AFT.

“Our approach of using continuous blending technologies along with the
largest micronization mills in the pharmaceutical space, make our offering
ideal for this product’s expected annual volumes and supply chain
requirements.

“The collaboration between our companies since the early days of formulation
development through clinical batches has been nothing short of spectacular
and we look forward to continued expansion of this relationship.”

AFT Pharmaceuticals Limited,
Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com

Additional manufacturing capacities for new launches
AFT has formed additional manufacturing agreements with separate
companies in Canada and Europe to expand manufacturing capacities to
support the launch of Crystaderm
®
into China. The launch, the first AFT product
to be launched in China, is planned for later in this 2024 year.
Dr Atkinson commented: “We are pleased to be putting these building blocks
in place in order to accelerate our international expansion plans. In larger
markets like China, it is important to have sufficient manufacturing capacity to
support a launch.”
Further Hikma agreement for Maxigesic/Combogesic IV
2
AFT has also recently expanded its co-operation with Hikma Pharmaceuticals
to extend its license for Maxigesic/Combogesic IV, the intravenous form of the
pain relief medicine, to Saudi Arabia, Iraq, and Jordan. Hikma is the licensee
of the medicine in the US where it was recently launched.
Mazen Darwazah, Hikma’s Executive Vice Chairman and President of Middle
East and North Africa (MENA), said: “Our agreement with AFT Pharmaceuticals
for Combogesic
®
IV – an important alternative for the treatment of acute pain
and fever – is an important milestone in delivering on our purpose of putting
better health, within reach, every day.
“As a leading healthcare company in MENA, we continue to expand our
pipeline in growing therapeutic areas and are committed to partnerships with
global players to expand our portfolio of high-quality medicines to patients in
the region.”
AFT Pharmaceuticals affiliates progress
AFT’s UK affiliate, AFT Pharmaceuticals UK has recently made its first launches
into the UK, including Combogesic tablets into Boots and Combogesic IV to
hospitals. Additional launches are planned during this 2024 year.
The group recently formed AFT Pharmaceuticals Canada and AFT
Pharmaceuticals US in order to further support product launches in those
markets. First product launches by our affiliates in both markets are planned
this 2024 year.
It has also acquired an existing product license in one European Nation for a
niche medicine which is being discontinued by a multinational
pharmaceutical company. This medicine is on the European Medicines
Agency list of essential medicines and AFT looks to seek approval in additional
EU Nations with sales to commence this 2024 year. To support the
commercialization of this and future products, AFT Pharmaceuticals Europe
has been strengthened with the hiring of a Quality Manager based in Ireland.

AFT Pharmaceuticals Limited,
Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com


Footnotes
1.https://www.microsize.com/wp-content/uploads/2024/02/Microsize-AFT-Supply-
Agreement-PR._final_2-28-2024-1.pdf
2.https://www.hikma.com/news/hikma-expands-its -agreement-with-aft-
pharmaceuticals-for-the-commercialisation-of-injectable-pain-medication-
combogesic-into-the-saudi-jordanian-and-iraqi-markets/

For and on behalf of AFT Pharmaceuticals Limited by Malcolm Tubby, Chief Financial
Officer.

For more information:
Investors Media
Dr Hartley Atkinson Richard Inder
Managing Director The Project
AFT Pharmaceuticals Tel: +64 21 645 643
Tel: +64 9488 0232

About AFT Pharmaceuticals
AFT is a growing multinational pharmaceutical company that develops, markets, and
distributes a broad portfolio of pharmaceutical products across a wide range of
therapeutic categories which are distributed across all major pharmaceutical
distribution channels: over the counter (OTC), prescription and hospital. Our product
portfolio comprises both proprietary and in-licensed products, and includes patented,
branded, and generic drugs
1
. Our business model is to develop and in-license
products for sale by our own dedicated sales teams in our home markets of Australia
and New Zealand and in certain Southeast Asian markets, and to out-license our
products to local licensees and distributors to over 125 countries around the world. For
more information about the company, visit our website www.aftpharm.com
.